Paclitaxel (AN)™
Active ingredients: Paclitaxel
Consumer medicine information
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
PACLITAXEL AN is indicated for the treatment of : Primart treatment of ovarian cancer in combination with a platinum agent; Treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; Adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; Treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin), in patients who have tumours that over-express HER-2 and who have not received previous chemotherapy for their metatastic disease; Treatment of non-small cell lung cancer (NSCLC); In combination with gemcitabine (Gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Source: ARTG
Storage conditions
- Shelf lifetime is 2 Years
- Store below 25 degrees Celsius
- Protect from Light
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Injection, solution
- Intravenous
- Clear colourless to yellow viscous solution.
Source: ARTG
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
- 1 x 16.7mL vial
Source: ARTG
Is this medicine subsidised?
This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Paclitaxel
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 4 November 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 4 November 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 November 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice
